3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
2
Thoracic
1
Dermatologic
1
Conditions
Breast Neoplasms
14
Brain Neoplasms
6
Ovarian Neoplasms
4
Melanoma
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms, Second Primary
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms, Male
1
Astrocytoma
1
Interventions
Temozolomide
2
sacubitril and valsartan sodium hydrate drug combination
1
Interviews as Topic
1
Cryosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
Temozolomide
×
Breast
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts
NCT00629187
2012-04-27
CN-306
Tufts Medical Center
Phase 1
Terminated
2 enrolled